secwatch.observer — SEC 8-K summary
======================================

Issuer:     REPLIGEN CORP (RGEN)
CIK:        0000730272
Form:       8-K
Filed at:   2022-06-01T23:59:59+00:00
Accession:  0001193125-22-165344
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repligen appoints Dr. Konstantin Konstantinov to board; all directors re-elected at annual meeting
--------------------------------------------------------------------------------

- Konstantinov elected to board effective May 26, 2022; brings 30 years of bioprocessing expertise from Genzyme and Bayer.
- Annual meeting results: all six director nominees elected with >94% support; Ernst & Young ratified as auditor; say-on-pay approved.
- Severance and change in control plan amended to adjust treatment of performance-based equity awards upon change in control.
- CEO Tony Hunt's employment agreement amended to align equity treatment with the amended severance plan.
- Director compensation policy amended for new non-employee director equity grants; new director granted initial option worth $170,000.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/730272/000119312522165344/0001193125-22-165344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/730272/000119312522165344/d339987d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-165344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer